Navigation Links
Arbor Pharmaceuticals Announces the Launch of Pediaderm(TM) HC Complete Kit - A Comprehensive Approach to the Management of Atopic Dermatitis
Date:3/9/2010

RALEIGH, N.C., March 9 /PRNewswire/ -- Arbor Pharmaceuticals ("Arbor"), a specialty pharmaceutical company focused exclusively on pediatric medicine, announced today that the company has launched Pediaderm™ HC Complete Kit – an innovative new product for the comprehensive management of atopic dermatitis.  Pediaderm HC Complete Kit contains Pediaderm HC (Hydrocortisone Lotion USP 2%) and patented Pediaderm Protective Emollient with Triple Synergy Technology™. Pediaderm HC Complete Kit has been specifically developed to treat, manage, and protect the skin of children with atopic dermatitis, commonly referred to as eczema.

Atopic Dermatitis (AD) is the most common chronic inflammatory skin condition among US children, and the prevalence is increasing worldwide(1). The American Academy of Dermatology recommends the use of topical corticosteroids to treat the acute flares of AD and the concomitant use of emollients to hydrate, protect and restore the skin(2).  Importantly, the presence of certain skin pathogens – most notably Staphylococcus aureus (S. aureus) – have been shown to contribute to the worsening and persistence of AD, while also contributing to problematic skin infections(3).

"Arbor is excited to introduce this novel and comprehensive approach to the treatment and management of atopic dermatitis for children suffering from this troubling disease.  The patented Triple Synergy Technology contained within the Pediaderm Protective Emollient is a unique technology that provides an innovative approach to treating AD.   As a pediatric pharmaceutical company our mission is to introduce novel products that offer better solutions for the most common childhood illnesses.  Pediaderm HC Complete Kit represents another important step for the company in fulfilling that mission," stated Jarrett Disbrow, President and CEO of Arbor Pharmaceuticals.  

Pediaderm HC Complete Kit is the first and only product that provides a comprehensive approach to treating and managing atopic dermatitis.  Pediaderm HC contains the lowest prescription-only dose of hydrocortisone in a child-friendly, fast-drying form and is safe to use on all ages and all areas of the body(4).  The patented Pediaderm Protective Emollient is a uniquely formulated cream specifically designed to rehydrate, replenish and restore the integrity of skin damaged by atopic dermatitis.  Importantly, Pediaderm Protective Emollient incorporates the patented Triple Synergy Technology™ which has been proven to eradicate a wide range of bacteria, fungi and viruses, including Staphylococcus aureus and Methicillin-resistant Staphylococcus aureus (MRSA), two common causes of skin infections which are often difficult to treat(5).

Pediaderm HC Complete Kit is available by prescription only at retail pharmacies across the U.S.  Pediaderm HC Complete Kit is directly promoted to U.S. pediatricians by Arbor Pharmaceuticals' specialty sales force.  Pediaderm HC Complete Kit is Arbor Pharmaceuticals' fourth product launch since the company initiated commercial operations less than two years ago.  

Important Safety Information

Pediaderm HC Complete Kit is available by prescription only.

Pediaderm HC Lotion

Pediaderm HC Lotion is for topical use only and should not be used ophthalmically.

Pediaderm HC Lotion is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Pediaderm HC is contraindicated in patients with a history of hypersensitivity to any of the components of the preparation. Prolonged use may produce reversible HPA axis suppression. Consider periodic evaluations for HPA axis suppression if applied to large surface areas or used under occlusion. Systemic effects of topical corticosteroids may also include manifestations of Cushing's syndrome, hyperglycemia, and glucosuria. Pediatric patients may be more susceptible to systemic toxicity due to their large skin surface-to-body-mass ratios. Initiate appropriate therapy if a concomitant skin infection develops. Patients may experience local adverse reactions, including burning, itching, irritation, and dryness. Discontinue use and contact your healthcare professional if irritation persists.

Pediaderm Protective Emollient

Pediaderm Protective Emollient is nonsteroidal and is intended for topical use only.

Pediaderm Protective Emollient is contraindicated in patients with a history of hypersensitivity to any of the components of the preparation. Discontinue use and contact your healthcare professional if irritation develops.

About Arbor Pharmaceuticals

Arbor Pharmaceuticals, headquartered in Raleigh, North Carolina, is a specialty pharmaceutical company focused exclusively on the growing pediatric market.  The company intends to become the leading pediatrics-focused pharmaceutical company by actively licensing, developing and commercializing late-stage products for significant pediatric conditions.  In addition to PEDIADERM™ HC COMPLETE KIT, Arbor also currently markets three nonantibiotic products for varying otic conditions including XYLAREX®, ZINOTIC® and NEOTIC®.    

For more information regarding Arbor Pharmaceuticals or any of its products, visit www.arborpharma.com or send email inquiries to info@arborpharma.com.

See www.pediaderm.com for full prescribing information.

(1) Horii KA, Simon SD, Liu DY, Sharma V. Atopic Dermatitis in Children in the United States, 1997 2004: Visit Trends, Patient and Provider Characteristic, and Prescribing Patterns. Pediatrics 2007; 120;e527-e534
(2) Hanifin J et al. Guidelines of care for Atopic Dermatitis. J Am Acad Dermatol; 2004; 50:391-404.

(3) Huang J, Abrams M, Tlougan B, Rademaker A, Paller A. Treatment of Staphylococcus aureus Colonization in Atopic Dermatitis Decreases Disease Severity. Pediatric; 2009; 123; e808-e814.

(4) Wolters Kluwer Health. Medispan-PriceRx 12/2009.

(5) Data on File. Arbor Pharmaceuticals, Inc.

Xylarex, Zinotic, and Neotic are registered trademarks of Arbor Pharmaceuticals, Inc.

SOURCE Arbor Pharmaceuticals

Back to top

RELATED LINKS
http://www.arborpharma.com

'/>"/>

SOURCE Arbor Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Harbor BioSciences to Receive Patent for Apoptone(R) Cancer Treatment
2. Hollis-Eden Announces Name Change to Harbor BioSciences, Inc. and Ticker Symbol Change to HRBR
3. Cold Spring Publishing, LLC, Changes Name to Harborside Press, LLC
4. Harborside Healthcare to Pay U.S. $1.375 Million to Resolve Allegations of Kickbacks and Sham Durable Medical Services
5. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory
6. DUSA Pharmaceuticals to Present at Roth Capital Partners 22nd Annual OC Growth Stock Conference
7. ISTA Pharmaceuticals Receives Action Date for FDA Review of Once-Daily XiDay(TM)
8. Ampio Pharmaceuticals, Inc. Retains Redwood Consultants, LLC to Assist in Shareholder Relations and Strategic Planning
9. Charles E. Lannon Was Appointed as Vice-Chairman of the Board of Directors at Kinex Pharmaceuticals
10. Chay Enterprises Inc. Completes Merger With Repurposed Drug Developer Ampio Pharmaceuticals, Inc.
11. Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... , March 30, 2017 The topical ... $92.40 billion in 2016, growing at a CAGR of 6.4% ... is will be major end-user in market. While ... forecast period. ... Browse 87 tables and 41 figures, 10 Company profiles ...
(Date:3/30/2017)... -- Research and Markets has announced the addition ... Forecast, By Type (Hemodialysis, Peritoneal Dialysis), By Product (Device, Consumables, ... To 2025" report to their offering. ... The global hemodialysis ... billion by 2025. Home-based dialysis treatment ...
(Date:3/29/2017)... Research and Markets has announced the addition of the ... ... energy-based aesthetic devices market to grow at a CAGR of 8.12% ... Aesthetic Devices Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
Breaking Medicine Technology:
(Date:3/29/2017)... Massachusetts (PRWEB) , ... March 30, 2017 , ... Youth ... had great success and feedback from high school and college students who have participated ... being held July 7-23 and YFI is now accepting applications for enrollment. Visit ...
(Date:3/29/2017)... ... March 30, 2017 , ... Sports Brand EXOUS Bodygear ... which retails normally at $29.97; for the remaining days of March, the price will ... reduced to a special price of just $10 (regular retail price $19.97). , The ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... ... three Hours at a Walgreens store in Mississippi. AngioGenesis Labs, makers of HeartBoost, ... Stores in two southeastern states. Ingredients in HeartBoost, an over the counter heart ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... provides insight into the challenges employers face in trying to balance both short-term ... employee benefits programs? Adding to the growing complexity, companies are finding that ...
(Date:3/29/2017)... ... March 29, 2017 , ... Dr. Angela Cotey, a noted general ... accepting new pediatric patients, with or without a referral. Dr. Cotey knows that ... orthodontic outcome and experience. When patients receive early treatment, they may achieve straight teeth ...
Breaking Medicine News(10 mins):